Core-binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22)/RUNX1-RUNX1T1 or inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11. The resulting fusion genes require a 'second hit' to initiate leukemogenesis. Mutation assessment of 177 adults with CBF-AML, including 68 with t(8;21) and 109 with inv(16)/t(16;16), identified not only mutations well known in CBF-AML but also mutations in the CCND1 and CCND2 genes, which represent novel frequent molecular alterations in AML with t(8;21). Altogether, CCND1 (n = 2) and CCND2 (n = 8) mutations were detected in 10 (15%) patients with t(8;21) in our cohort. A single CCND2 mutation was also found in 1 (0.9%) patient with inv(16). In contrast, CCND1 and CCND2 mutations were detected in only 11 (0.77%) of 1426 non-CBF-AML patients. All CCND2 mutations cluster around the highly conserved amino-acid residue threonine 280 (Thr280). We show that Thr280Ala-mutated CCND2 leads to increased phosphorylation of the retinoblastoma protein, thereby causing significant cell cycle changes and increased proliferation of AML cell lines. The identification of CCND1 and CCND2 mutations as frequent mutational events in t(8;21) AML may provide further justification for cell cycle-directed therapy in this disease.
INTRODUCTION
Acute myeloid leukemia (AML) with t(8;21)(q22;q22)/RUNX1-RUNX1T1 (hereafter referred to as t (8;21) ) and AML with inv(16) (p13q22)/CBFB-MYH11 or t(16;16)(p13;q22)/CBFB-MYH11 (hereafter referred to as inv (16) ) are related at the molecular level. The fusion genes created by the aforementioned chromosome rearrangements disrupt, respectively, subunits α and β of core-binding factor (CBF), a heterodimeric transcription factor involved in hematopoietic differentiation, and impair its function. 1 Consequently, both these AML types are together referred to as CBF-AML, 1, 2 and each of them is recognized by the World Health Organization classification of myeloid neoplasms and acute leukemia as a distinct disease entity. 3 CBF-AML is relatively frequent, with t(8;21) detected in approximately 6% and inv (16) in approximately 7% of adults with de novo AML. 2 Patients with CBF-AML, compared with other AML subtypes, have a relatively favorable prognosis, especially with the use of high-dose cytarabine-based postremission chemotherapy. However, almost 40% of CBF-AML patients experience relapses of their disease. 4, 5 Patients with t(8;21) were reported to have shorter overall survival (OS) and survival after first relapse than patients with inv(16). 4, 5 Although the RUNX1-RUNX1T1 and CBFB-MYH11 fusion genes are essential, disease-defining contributors to leukemogenesis, they are not capable of causing leukemia by themselves. 2, 6 The presence of additional genetic alterations, including mutations in the KIT, NRAS, KRAS or FLT3 (especially mutations in the tyrosine kinase domain of FLT3 (FLT3-TKD)) genes, likely represent a 'second hit' to initiate leukemogenesis. 2, 6 Thus elucidation of the full mutational spectrum of both cytogenetic types of CBF-AML is of high importance. Although some previously reported molecular features of CBF-AML, such as KIT and RAS mutations, are shared by both t(8;21)-and inv(16)-positive CBF-AML, mutations in the cohesin complex and chromatin remodeling genes are more frequently found in AML with t(8;21) than in AML with inv (16) . 7, 8 The recent discoveries of recurring mutations in ASXL2 9 and ZBTB7A 10,11 that occur either exclusively (ASXL2 9, 11 ) or almost exclusively (ZBTB7A 10, 11 ) in t(8;21)-positive CBF-AML further support the existence of specific mutations that distinguish patients with t(8;21) from those with inv (16) .
A recent comprehensive study of gene mutations in CBF-AML 7 detected the presence of at least one mutation in 85% of the patients studied, thus leaving a possibility that the remaining 15% of patients harbor other, as yet not discovered, mutations. Therefore, we hypothesized that novel, hitherto not reported gene mutations may still exist and, if so, that they might contribute to clinical and molecular differences between CBF-AML patients with t(8;21) and those carrying inv (16) . We analyzed samples from a relatively large cohort of adults with CBF-AML for mutations in 84 leukemia-and/or cancer-associated proteincoding genes using a customized targeted next-generation sequencing approach. Herein we report for the first time recurrent mutations in the cyclin D1 (CCND1) and cyclin D2 (CCND2) genes as the third most common mutational event in patients with t(8;21), but not in those with inv (16) . Cyclins CCND1 and CCND2 have a crucial role in the regulation of hematopoietic differentiation and cell proliferation, 12 and their differential activation has been implicated in leukemogenesis. 12, 13 Although CCND1 and CCND2 mutations are relatively frequent mutational events in solid tumors (as evidenced by The Cancer Genome Project (TCGA) studies), they have not yet been described as frequent recurrent events in hematological malignancies, including t(8;21) AML.
PATIENTS AND METHODS

Patients, treatment and cytogenetic studies
We analyzed all pretreatment bone marrow (BM) or peripheral blood (PB) samples suitable for next-generation sequencing, which were obtained from 177 adult AML patients diagnosed with CBF-AML and treated similarly on Cancer and Leukemia Group B (CALGB)/Alliance for Clinical Trials in Oncology (Alliance) trials. In addition, pretreatment BM or PB samples of 81 adults with CBF-AML who were also treated on the aforementioned CALGB/Alliance trials and whose samples were of insufficient DNA quality (260/280 ratio 41.6) or quantity (100 ng DNA) were analyzed for their CCND1 and CCND2 mutation status using Sanger sequencing. Details of the treatment studies are provided in Supplementary Information. Cytogenetic analyses of pretreatment BM and/or PB samples were performed by institutional laboratories approved by the CALGB/Alliance. Cytogenetic results were confirmed by central karyotype review.
14 Patients provided written informed consent to participate in protocols CALGB 8461 (cytogenetic studies), CALGB 9665 (leukemia tissue bank) and CALGB 20202 (molecular studies), which involved collection of pretreatment BM aspirates and PB samples. Study protocols were in accordance with the Declaration of Helsinki and approved by the institutional review boards at each center, and all patients provided written informed consent.
Statistical analyses
Baseline characteristics were compared between patients harboring mutations of the CCND1 or CCND2 genes and those with wild-type CCND1 and CCND2 using Fisher's exact test for categorical variables and Wilcoxon rank-sum test for continuous variables. A P-value of ⩽ 0.05 was considered statistically significant. P-values for proliferation and cell cycle analyses were calculated using two tailed t-tests, and Welch's correction was applied when the variances between groups were unequal as indicated by a significant F-test. Definitions of the clinical end points-complete remission (CR), disease-free survival (DFS) and OS-are provided in Supplementary Information. The data set was locked on 21 January 2016. Data collection and statistical analyses were performed by the Alliance Statistics and Data Center using SAS 9.4 (SAS, Raleigh, NC, USA).
Molecular analyses
Mononuclear cells were enriched through Ficoll-Hypaque gradient centrifugation and cryopreserved until use. Genomic DNA was extracted using the DNeasy Blood and Tissue Kit (QIAGEN, Hilden, Germany). The mutational status of 84 protein-coding genes was determined centrally at The Ohio State University by targeted amplicon sequencing using two different gene panels on the MiSeq platform (Illumina, San Diego, CA, USA; see Supplementary Information for details). The panels comprised the following genes: AKT1, ARAF, ASXL1, ASXL2, ATM, AXL, BCL2, BCOR, BCORL1, BIRC6, BRAF, BRD4, BRINP3, BTK, CALR, CBL, CCND1, CCND2, CEBPA (bi-allelic), CSNK1A1, CTNNB1, DHX15, DNMT3A, ETV6, EZH2, FBXW7, FLT3 (for FLT3-TKD), GATA1, GATA2, GSK3B, HIST1H1E, HNRNPK, IDH1, IDH2, IKZF1, IKZF3, ILR7, JAK1, JAK2, JAK3, KIT, KLHL6, KMT2A, KRAS, MAPK1, MAPK3, MED12, MYD88, NOTCH1, NPM1, NRAS, PHF6, PIK3CD, PIK3CG, PLCG2, PLEKHG5, PRKCB, PRKD3, PTEN, PTPN11, RAD21, RAF1, RUNX1, SAMHD1, SETBP1, SF1, SF3A1, SF3B1, SMARCA2, SMC1, SMC3, SRSF2, STAG2, SYK, TET2, TGM7, TP53, TYK2, U2AF1, U2AF2, WT1, XPO1, ZMYM3, and ZRSR2. The MuCor program 15 was used for initial data analysis, followed by visual inspection and quality control of the BAM files. If o 15 reads were present, the gene mutation status was considered as not evaluable. The variant allele fraction cutoff for reporting mutations was set to 0.10. CCND1 and CCND2 mutations above and below the threshold were additionally validated by Topo-TA cloning of the PCR product, followed by Sanger sequencing. Variants (missense, nonsense or frameshift) were considered as mutations if they were not reported in the 1000 Genome database, dbSNP137 or dbSNP142. Testing for the presence or absence of FLT3 internal tandem duplication was performed as previously described. 16 Tissue culture KG1a and Kasumi-1 cells (both CCND1 and CCND2 wild type) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) for studying the effects of the CCND2 Thr280Ala mutation in AML. Both cell lines were authenticated by ATCC using the cytochrome C oxygenase 1 gene assay for interspecies determination, and short tandem repeat analysis for intraspecies determination of the unique DNA profiles. The cells were cultured in RPMI medium supplemented with 10% fetal bovine serum and 1% Antibiotic-Antimycotic (Gibco, Big Cabin, OK, USA).
Forced abundance of CCND2 Thr280Ala, wild-type CCND2 and empty vector (EV) control
The open reading frame of wild-type CCND2 and CCND2 harboring the Thr280Ala mutation were cloned into an HIV-based lentiviral dual promoter vector (pCDH-CMV-MCS-EF1-copGFP+Puro cDNA; System Biosciences, Palo Alto, CA, USA) for stable expression. The mutation was introduced using a 1-basepair mismatch reverse primer. Primer sequences were as follows: CCND2 clone F, 5′-GCGTGCTAGCATGGAGCTGCTGTGCC ACGAG-3′; CCND2 clone R, 5′-GCGTGAATTCCTCACAGGTCGATATCCCG CACGTCTGTAGGGTTG-3′; and CCND2 mutR, 5′-CAGCAACCCTACAGACGTG CGGGATATCGACCTGTGAGGAT-3′ (System Biosciences). The lentiviral construct (45 μg) was transfected into HEK-293TN cells using 45 μl pPACKH1 and 55 μl PureFection (System Biosciences). The supernatant containing the pseudoviral particles was collected after 48 and 72 h, and the virus was precipitated at 4°C overnight using 5 × PEG-IT virus precipitation solution (System Biosciences). Two hundred microliters of phosphate-buffered saline and 25 μM Hepes Buffer were used for resuspension of the pelleted virus. We infected 200 000 cells in triplicate with 20 IU of virus using 5 μl Transdux Infection Reagent (System Biosciences). RNA was harvested after 72 h, and CCND2 overexpression was confirmed at the RNA and protein level.
TiterGlo assays
Cell viability changes in cell lines infected with CCND2 Thr280Ala, CCND2 wild type or EV control were analyzed using chemiluminescent TiterGlo assays (Promega, Madison, WI, USA) 72 h after puromycin selection (cell lines) using 20 000 cells in duplicate from three biological replicates according to the manufacturer's instructions.
Immunofluorescence staining and microscopy
Staining was performed on puromycin-selected cells by standard procedures using the following antibodies: Phospho-HistoneH3 (sc-101752, Santa Cruz Biotechnology, Dallas, TX, USA), and Alexa Fluor 488 goat anti-mouse (A-11001, Thermo Fisher Scientific, Waltham, MA, USA). Micrographs were captured using a BZ-9000 microscope (Keyence, Osaka, Japan).
Propidium iodide flow cytometry cell cycle analysis
Cell lines expressing CCDN2 Thr280Ala, wild-type CCND2 or EV were fixed in ethanol, treated with RNAse A and then suspended in propidium iodide. Fluorescence-activated cell sorting was performed by BD LSR II cytometry (Beckman-Coulter, Brea, CA, USA) with assistance from The Ohio State University Analytic Cytometry Core. Cell cycle analysis was performed with the FlowJo software v7.6.3 (FlowJo LLC, Ashland, OR, USA) using the Watson model and no constraints.
Recurrent CCND1 and CCND2 mutations in t(8;21) AML A-K Eisfeld et al RESULTS Differences in the molecular landscapes of CBF-AML with t(8;21) and CBF-AML with inv (16) The baseline clinical characteristics of all 177 CBF-AML cases are listed in Supplementary Table S1 . Molecular profiling not only showed mutational events that were shared by patients with t(8;21) and those with inv(16) with a similar incidence but also revealed mutational features that were more frequent in one of the two CBF-AML subtypes. As a group, mutations in genes encoding kinases were the most frequent both in patients with t(8;21) and those with inv(16)─they were found in 33% of the former and 32% of the latter (Figure 1a and Supplementary Table S2 ). Interestingly, mutations in specific chromatin remodeling genes were tightly associated with each cytogenetic type of CBF-AML, with ASXL2, EZH2, ASXL1 and SMARCA2 mutations occurring exclusively or almost exclusively in patients with t(8;21), and BCORL1 and BCOR mutations being found predominantly in patients with inv(16) (Supplementary Table S3 ). Likewise, mutations in the cohesion complex were observed only in patients with t(8;21) (15% vs 0% in inv(16), Po 0.001). This is in line with previous reports, 7 as is a lower incidence of RAS pathway mutations in patients with t(8;21), which were found in 19% of patients, as compared with 35% of the inv(16) patients with RAS pathway mutations (P = 0.03).
Identification of recurrent CCND1 and CCND2 mutations in patients with t(8;21) Strikingly, in addition to the known mutations, we detected recurrent mutations in the CCND1 and CCND2 genes. In fact, CCND1 and CCND2 mutations were the third most frequent mutational events in patients with t(8;21) (together with NRAS mutations), being detected in 10 of the 68 (15%) such patients (Figure 1b) . The variant allele fractions of the detected CCND1 and CCND2 mutations were variable, suggesting that these mutations can represent both early and later mutational events (Table 1) . Only one CCND2 mutation was found in 109 (0.9%) patients with inv (16) . Similarly, when we used Sanger sequencing to test for CCND1 and CCND2 mutations in pretreatment samples from an additional set of 81 CBF-AML patients for whom next-generation sequencing was not possible (inv (16) , n = 56; t(8;21), n = 25)), we detected CCND1 and CCND2 mutations in three patients with t(8;21), one of whom had a CCND1 mutation and two carried CCND2 mutations. As a result, the overall CCND1 and CCND2 Figure 1 . (a) Oncoprint of mutations found in CBF-AML patients with t(8;21) and those with inv (16) showing mutation status of the CCND1 and CCND2 genes (red color-mutated, white-wild type) and of genes classified into the previously described functional groups. 22 Each column represents an individual patient. A star indicates the presence of two different CCND1 or CCND2 mutations in the same patient. Green color indicates that at least one gene belonging to a given functional group was found to be mutated in the patient, white color indicates wild-type status of all genes from this functional group. The exact numbers of specific gene mutations detected in each functional group are provided in Supplementary Table S3 . (b) Bar graphs depicting the frequencies of the five most common gene mutations accompanying t(8;21) (green) and inv(16) (white) in CBF-AML patients. CCND1 and CCND2 mutations were the third most frequent gene mutations in patients with t(8;21). In contrast, CCND1 and CCND2 mutations were rare in patients with inv(16). mutation frequency among a total of 93 patients with t(8;21) tested was 14%. No additional CCND1 or CCND2 mutations were found among 56 patients with inv(16) analyzed using Sanger sequencing. Thus CCND1 and CCND2 mutations represent a novel mutational feature, which further distinguishes CBF-AML with t(8;21) from CBF-AML with inv(16) at the molecular level. Interestingly, among patients with t(8;21), two of the eight CCND2-mutated patients and one of the two CCND1-mutated patients had multiple mutations in these genes (Figure 1 ), which likely occurred in separate subclones, suggesting that CCND1 and CCND2 mutations have an important role in leukemogenesis.
Differential activation of cyclin genes is a known contributor to leukemogenesis. 12, 13 The identified molecular mechanism responsible for the stabilization of the CCND2 protein is the inhibition of glycogen synthase kinase 3 beta through Janus kinase 2 and phosphatidylinositol 3′ kinase signaling, which is responsible for phosphorylation of CCND2 at amino-acid threonine 280 (Thr280), followed by proteasomal degradation of CCND2. 17 Intriguingly, all CCND2 mutations we detected in t(8;21) patients either directly affected (n = 5) or clustered around the codon Thr280, thereby also involving highly conserved amino-acid residues Lys234, Glu274, Gln277 and Pro281 (twice; Figure 2a ). The mutations in codon 280 replace threonine with either alanine or asparagine, both of which are the exact amino-acid changes that have been previously found to render CCND2 resistant toward proteasomal degradation, 17, 18 resulting in a constitutively active CCND2
protein. Furthermore, de novo germline CCND2 mutations affecting the identical amino-acid residues Thr280 or Pro281 have been recently found to cause megalencephaly-polymicrogyriapolydactyly-hydrocephalus syndrome (MPPH) type 3, an extremely rare neurodegenerative disorder. 18 Although no increased cancer or leukemia risk has been reported to date for this patient population, Mirzaa et al. 18 observed strongly increased proliferation of embryonic mouse brain cells after introduction of the CCND2 Thr280Ala mutant.
The CCND1 mutations detected in our patients with t(8;21) affected amino-acid positions Thr286, Arg291 and Val293. Similarly to the data regarding cyclin D2, it has been previously shown CCND1 turnover is dependent on Thr286 phosphorylation and is regulated by ubiquitin-dependent proteasomal degradation (Supplementary Figure S1) . Phosphorylation of CCND1 was enhanced by binding to CDK4 and mutation of Thr286 to alanine (Thr286Ala) resulted in increased stability of the cyclin. 19 Furthermore, overexpression of CCND1 Thr286Ala also facilitated anchorage-independent growth of NIH-3T3 cells in soft agar, suggestive of a transformatory potential. 20 Clinical and molecular characterization of CBF-AML patients with t(8;21) and CCND1 or CCND2 mutations Detailed clinical and cytogenetic information on the affected patients, the CCND1 and CCND2 mutation locations and observed Patients 12-14 were analyzed for their CCND1 and CCND2 mutation status using Sanger sequencing. Thus, for these patients, read depth, VAF and information on the presence or absence of additional mutations are not available.
Recurrent CCND1 and CCND2 mutations in t(8;21) AML A-K Eisfeld et al variant allele fractions and additional mutations found in the patients (if known) are listed in Table 1 and Supplementary Table  S5 . The evaluation of mutations in other genes found in these patients did not reveal any statistically significant co-occurring or mutually exclusive mutations (Figure 2b) . The most frequent cooccurring mutation was ASXL2, which we detected in 4 of the 10 (40%) cases with t(8;21). As mutations in the receptor tyrosine kinase/RAS/phosphatidylinositol 3′ kinase pathway are frequent in AML patients with t(8;21), the identification of CCND2 mutations adds a new key player to the already known mutations and further highlights the importance of this pathway in leukemogenesis in t(8;21)-positive patients (Figure 2c ). 21 We also compared pretreatment clinical features and outcomes of patients with t(8;21) with CCND1 and CCND2 mutations with those of patients with wild-type CCND1 and CCND2 genes (Tables 2 and 3 ). Patients with CCND1 and CCND2 mutations presented with lower percentages of PB (P = 0.02) and BM (P = 0.05) blasts than patients without these mutations but did not differ significantly with regard to other pretreatment characteristics (Table 2) . No outcome differences were observed between CCND1-and CCND2-mutated and CCND1 and CCND2 wild-type patients. All but one patient with CCND1 and CCND2 mutations (88%) evaluated for outcome achieved a complete remission after induction chemotherapy, which is similar to the response rates seen in CCND1 and CCND2 wild-type patients (Table 3) . Three CCND1-and CCND2-mutated patients relapsed within the first year.
Functional consequences of the CCND2 Thr280Ala mutation in AML Thr280Ala and Thr280Asn, the most frequently detected mutations in our patient cohort, were both previously found to result in a constitutively active CCND2 protein. 17, 18 To gain insights into the effects of the CCND2 mutations in AML, we stably introduced the CCND2 Thr280Ala mutant into AML cell lines KG1a and Kasumi-1 and compared the effects of the mutant on cell proliferation with wild-type CCND2 and EV control. Notably, the Kasumi-1 cell line harbors the t(8;21) translocation. Introduction of CCND2 T280A significantly increased cell growth (as assessed by TiterGlo assays and cell counts, Figure 3a ) in all experimental set-ups. Western blotting revealed a strong increase of retinoblastoma gene phosphorylation (P-Rb, Figure 3b) , 22 indicating increased downstream signaling. Moreover, both propidium iodide-mediated cell cycle analysis (Figure 3c ) and immunofluorescence staining for phospho-histone H3 (Figure 3d ) indicated an increased mitotic rate and a decreased G1 fraction.
Frequencies of CCND1 and CCND2 mutations in adult non-CBF-AML patients The extensive sequencing study performed by TCGA did not report a single CCND1 or CCND2 mutation in 200 AML patients analyzed. 23 The Catalogue of Somatic Mutations in Cancer lists only nine CCND2 mutations in hematological malignancies, five of which were found in patients with AML, whose cytogenetic and clinical features have not been reported. To determine frequencies of CCND1 and CCND2 mutations in non-CBF-AML patients, we performed targeted next-generation sequencing of a large cohort of 1426 adult patients with AML, which comprised patients with a wide spectrum of cytogenetic findings (with the exception of acute promyelocytic leukemia). We detected only five CCND1 mutations and six CCND2 mutations (for an overall CCND1 and CCND2 mutation frequency of 0.77%). Pretreatment clinical, cytogenetic and molecular characteristics of these patients are provided in Supplementary  Table S4 . Four of the six CCND2 mutations were located at, or in the proximity of, the mutation hotspot Thr280. All but one of the patients with mutations were aged o 60 years. Ten of the 11 cases were cytogenetically normal, whereas 1 patient had a unique balanced translocation t(2;13)(p23;q14) and trisomy 21. Although 9 of the 11 (82%) CCND1-and CCND2-mutated patients achieved a complete remission, 7 of the 9 (78%) patients relapsed within the first year after cytarabine/daunorubicin-based chemotherapy.
DISCUSSION
Enhancing our understanding of the molecular alterations in CBF-AML is of major importance, because it may not only help explain the differences in the clinical features between patients with t(8;21) and those with inv(16) but also lead to identification of new mutated genes encoding abnormal molecules, which may be potential therapeutic targets.
In this study, we comprehensively characterized the molecular landscapes of both cytogenetic subgroups of CBF-AML. The salient finding of our study is the discovery of mutations in the cyclin genes CCND1 and CCND2 as novel and relatively frequent mutational events, occurring almost exclusively in CBF-AML patients with t(8;21). Two aspects make this discovery especially intriguing. First, the fact that CCND1 and CCND2 have long been recognized as important players in hematopoietic development and leukemogenesis, 12, 13, 17 but frequent mutations in these genes were not reported in AML so far. This is especially noteworthy as the pathophysiological importance of the phosphorylation changes at the exact mutation hotspot we identified, at CCND2 amino-acid position Thr280 (and the corresponding phosphorylation site of CCND1, Thr286 20 ), have been intensively studied. Thr280 has even been proposed previously as drug targets in AML. 17 Second, the mutations in CCND1 and CCND2 seem to be a perfect fit into the mutational landscape of CBF-AML with t(8;21), which is dominated by receptor tyrosine kinase, RAS and chromatin remodeling gene mutations-all of which can result in targeting of CCND1 and CCND2. 21 Another aspect of our discovery of CCND1 and CCND2 mutations concerns the fact that several somatic mutations found in AML occur at the exact genomic locations as the germline changes known to be causative of rare, often neurodegenerative, syndromes. Similar to PTPN11 mutations in Noonan syndrome, 24 EZH2 mutations in Weaver syndrome, 25 SMARCA2 mutations in Nicolaides-Baraitser syndrome 26 and cohesion complex gene mutations in Cornelia de Lange syndrome, 27 CCND2 mutations affecting the identical amino acids were shown to cause MPPH syndrome. 18 MPPH syndrome is characterized by polymicrogyria, megalencephaly, intellectual disability, seizures, polydactyly, low muscle tone, skin elasticity and hydrocephalus. That no increased risk of leukemia has been reported to date in this patient population seems to support the hypothesis that CCND2 mutations are not sufficient themselves to cause neoplastic disease but rather serve as a second hit in CBF-AML with t(8;21). The fact that CCND2 mutations detected in CBF-AML patients with t(8;21) and the germline mutations causative of MPPH syndrome share the exact genomic location is especially noteworthy as CCND2 mutations in solid tumors are spread throughout the gene and are not preferentially found at position Thr280 (www. cbioportal.com).
In our study, we did not observe significant differences in the outcomes of t(8;21) patients with and without mutations in CCND1 and CCND2. This may be due to the relatively small sample size or may reflect the common use of cell cycle affecting high-dose cytarabine-based therapy in CBF-AML patients. However, 43% of CCND1-and CCND2-mutated t(8;21) patients and 78% of CCND1-and CCND2-mutated non-CBF-AML patients relapsed with their disease. Given the broad experience with drugs targeting aberrantly activated CCND1 and CCND2 in other cancers, 28 exploration of those inhibitors in management of AML patients with CCND1 and CCND2 mutations, 29 both those with CBF-AML and the rare patients with CN-AML, may be of clinical importance.
In summary, the identification of recurrent CCND1 and CCND2 mutations in patients with t(8;21) increases our understanding of the mutational landscape of CBF-AML and further highlights the critical importance of receptor tyrosine kinase/RAS/CCND pathway activation in the biology of t(8;21) AML. 
